Literature DB >> 2865903

Down-regulation of central dopamine receptors in schizophrenia.

F P Zemlan, R J Hitzemann, J Hirschowitz, D L Garver.   

Abstract

CSF homovanillic acid (HVA) levels reflecting central dopamine release and apomorphine-stimulated human growth hormone (HGH) secretion reflecting central dopamine receptor activity were concomitantly determined in 20 schizophrenic patients. There was a strong negative correlation between HVA and HGH levels: high dopamine release was associated with lower HGH responses to dopamine receptor activation by apomorphine. Studies are reviewed which suggest that the presently observed relationship reflects release-mediated down-regulation of central D2 receptors, the dopamine receptor subtype associated with the antipsychotic properties of neuroleptic medication.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865903     DOI: 10.1176/ajp.142.11.1334

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  3 in total

1.  Diminished synaptosomal dopamine (DA) release and DA autoreceptor supersensitivity in schizophrenia.

Authors:  L Hetey; R Schwitzkowsky; T Ott; H Barz
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 2.  Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.

Authors:  A N Wadworth; R C Heel
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.